Novo Nordisk has officially launched its groundbreaking weight-loss drug, Wegovy, in China, marking a significant step in addressing obesity in the world’s most populous country. The drug’s approval by Chinese health authorities in June has paved the way for its introduction into the second-largest pharmaceutical market globally.

A Solution for 180 Million Obese Individuals in China

With over 180 million people in China living with obesity, the demand for effective weight-loss treatments is higher than ever. Wegovy, priced at 1,400 yuan (£153; $194) for a pack of four injections, is substantially more affordable than its cost in the United States, where a month’s supply is priced at $1,349. However, Chinese patients will need to bear the full expense of the drug, as it is not yet covered under the country’s national healthcare insurance system.

What Makes Wegovy Stand Out?

Wegovy contains semaglutide, a highly effective active ingredient also found in Novo Nordisk’s diabetes drug Ozempic. Semaglutide works by regulating blood sugar, reducing appetite, and creating a feeling of fullness, helping patients lose more than 10% of their body weight on average.

Novo Nordisk emphasized on WeChat that Wegovy offers a “safe and effective weight loss option” for overweight and obese patients.

The Growing Global Popularity of Wegovy

Since its U.S. debut in 2021, Wegovy has gained immense popularity, partly due to social media endorsements and high-profile users like Elon Musk. The buzz surrounding the drug has driven demand to record levels, solidifying Novo Nordisk’s position as Europe’s most valuable company with a market valuation exceeding $440 billion.

Challenges and Side Effects

Despite its success, Wegovy has faced some challenges. Side effects such as nausea and vomiting have been reported, and research suggests that patients often regain weight after discontinuing the treatment. In the UK, health authorities have issued warnings about the misuse of obesity injections, particularly among non-obese individuals, which has led to adverse health effects.

Competition on the Horizon

Wegovy’s introduction in China comes as Eli Lilly prepares to enter the same market with its own highly anticipated weight-loss treatment. This sets the stage for a competitive battle between two pharmaceutical giants, both aiming to dominate a rapidly growing industry.

A Step Towards Tackling the Obesity Epidemic

With China emerging as a key market for weight-loss solutions, Wegovy represents a significant development in the fight against obesity. By offering an effective treatment tailored to the needs of millions, Novo Nordisk has made a bold move toward reshaping health outcomes in the region.